Esophagus cancer
Conditions
Interventions
Experimental group:Patients in the experimental group will undergo radical concurrent radiochemotherapy, with a total radiation dose of 50.4Gy/28Fx for the primary esophageal lesion and related metast
Control group:Patients in the control group will receive radical concurrent chemoradiotherapy, with a total radiotherapy dose of 50.4 Gy delivered in 28 fractions targeting the primary esophageal lesi
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
All
Age
70 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Sign the informed consent form; 2. Age>=70 years; 3. Histologically confirmed esophageal squamous cell carcinoma, naïve treatment (no surgery/radiotherapy/chemotherapy and targeted therapy); 4. Elderly patients with esophageal squamous cell carcinoma who are inoperable, unwilling to undergo surgery, and willing to undergo radiotherapy; cII-IVa (UICC 8th, including stage IV.b of supraclavicular lymph node metastases, excluding stage IV.b of other distant metastases) 5. No serious hematopoietic function, abnormal heart, lung, liver, kidney function and immune deficiency; 6. Normal organ and bone marrow function, defined as follows: white blood cell count >=4,000/µL, hemoglobin >=9 g/dL (without blood transfusion), neutrophil count >=2,100/µL, platelet count >=100, 000/µL, total bilirubin 3 months; 10. There is no primary tumor in other parts before treatment, or there is a primary tumor in other parts but has been controlled for more than 5 years.
Exclusion criteria
Exclusion criteria: 1. Esophageal perforation or hematemesis; 2. Secondary primary tumors (except cured non-malignant melanoma of the skin, thyroid papillary carcinoma, spermatogonial carcinoma stage I, cervical carcinoma in situ or other "curable" tumors that survive for more than 3 years after treatment); 3. Used other investigational drugs or participated in other clinical trials in the 30 days prior to randomization; 4. Drug addiction, long-term alcoholism, and AIDS patients; 5. Myocardial infarction time Patients who need myocardial thallium angiography at 6 months to show no myocardial ischemia and whose cardiologist agrees chemotherapy can be included in the study. 6. Uncontrollable seizures, or loss of self-awareness due to mental illness; 7. People with a history of severe allergies or specific constitutions; 8. Researchers consider it inappropriate to participate in this experiment; 9. Received radiation therapy in the intended radiotherapy area.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free Survival;Overall Survival;Safety; | — |
Countries
China
Contacts
Public ContactYe Jinjun, Zhou Guoren
Jiangsu Cancer Hospital
Outcome results
None listed